{"analyses":[{"ciLowerLimit":"0.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.1","estimateComment":"The Kaplan Meier method was used to estimate the median OS (in months) for the population. The Greenwood method was used to estimate the confidence limits of the median overall survival.","groupIds":["OG000"],"nonInferiorityComment":"Estimation only","nonInferiorityType":"OTHER","paramType":"Median","paramValue":"3.1"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"6.1","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Overall survival was defined as the duration from enrollment date to the date of death from any cause. Subjects who were alive or lost to follow-up at the time of the analysis were censored at the last known date they were alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"This group contains all subjects enrolled on the study, who received crizotinib, pooling the subjects in the three molecularly defined cohorts.","id":"OG000","title":"Total Enrolled Study Cohort"}],"paramType":"MEDIAN","populationDescription":"Study was designed to evaluate outcomes overall for all enrolled subjects and not separately by molecular cohorts. Efficacy analyses were conducted on the population of subjects who began crizotinib treatment.","reportingStatus":"POSTED","timeFrame":"From date of treatment start to date of death, or censored as described above; assessed for approximately 2 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}